Drug Profile


Alternative Names: arylsulfatase B; Aryplase™; BM 102; Naglazyme; Recombinant human arylsulfatase B; recombinant human N-acetylgalactosamine-4-sulfatase; rhASB

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioMarin Pharmaceutical
  • Developer AnGes MG; BioMarin Pharmaceutical; Medison Pharma
  • Class Arylsulfatases; Recombinant proteins
  • Mechanism of Action N acetylgalactosamine 4 sulfatase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis VI
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Mucopolysaccharidosis VI

Most Recent Events

  • 25 Nov 2011 Launched for Mucopolysaccharidosis VI in Russia (IV)
  • 06 Apr 2011 Launched for Mucopolysaccharidosis VI in Switzerland (IV)
  • 31 Dec 2010 Launched for Mucopolysaccharidosis VI in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top